A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma.

Abstract:

BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the validity, reliability and responsiveness of a parent-child dyad approach to utility and HR-QOL assessment of paediatric asthma health states. METHODS:The setting was specialist care in a hospital-based asthma clinic. Participants were 91 girls and boys with asthma aged 8 to 17 years and 91 parents. The intervention employed was parent-child dyad administration of the Health Utilities Index (HUI) 2 and 3, the Pediatric Quality of Life Inventory™ (PedsQL™) Core and Asthma modules, and the Pediatric Asthma Quality of Life Questionnaire (PAQLQ). Questionnaires were administered by interview to children and parents separately and then together as a dyad to assess the child's health state. The dyad interview was repeated at the next clinic visit. Dyad-child agreement was measured by intra-class correlation (ICC) coefficient; Spearman correlations were used to assess convergent validity. Test-retest reliability was assessed in 28 children who remained clinically stable between visits with a two-way ICC coefficient. Responsiveness to change from baseline was assessed with Spearman coefficients in 30 children who demonstrated clinical change between visits. RESULTS:There was no significant agreement between parent and child for the HUI2 or HUI3 whereas agreement between dyad and child was 0.55 (95% confidence interval [CI] 0.36, 0.69) for the HUI2 and 0.74 (95% CI 0.61, 0.82) for the HUI3 overall. With respect to dyad performance characteristics, both HUI2 and HUI3 overall scores demonstrated moderate convergent validity with the generic PedsQL™ Core domains (range r = 0.30-0.52; p < 0.01). Dyad HUI2 attributes demonstrated moderate convergent validity with the generic PedsQL™ Core domains of similar constructs (range r = 0.35-0.43; p < 0.001) and weaker convergent validity with disease-specific domains (range r = 0.13-0.32). Dyad HUI3 attributes demonstrated weaker convergent validity compared with the HUI2. For the assessment of test-retest reliability, significant agreement between baseline and follow-up was observed for dyad HUI2 total (r = 0.53), dyad PedsQL™ Core summary (r = 0.70) and select dyad disease-specific domains. Significant responsiveness (r > 0.4; p < 0.05) was observed for dyad HUI2 total score change over time as correlated with dyad HUI3, dyad PedsQL™ Core summary and select disease-specific domains. CONCLUSIONS:The parent-child dyad approach demonstrated moderate to strong performance characteristics in generic and disease-specific questionnaires suggesting it may be a valuable alternative to relying on parent proxies for assessing children's utility and HR-QOL. Future research in additional paediatric populations, younger children and a population-based sample would be useful.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Ungar WJ,Boydell K,Dell S,Feldman BM,Marshall D,Willan A,Wright JG

doi

10.2165/11597890-000000000-00000

subject

Has Abstract

pub_date

2012-08-01 00:00:00

pages

697-712

issue

8

eissn

1170-7690

issn

1179-2027

pii

6

journal_volume

30

pub_type

杂志文章
  • Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.

    abstract:BACKGROUND:National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices regarding how to model values from the coll...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11595420-000000000-00000

    authors: Augestad LA,Rand-Hendriksen K,Kristiansen IS,Stavem K

    更新日期:2012-12-01 00:00:00

  • Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

    abstract:BACKGROUND:Invasive fungal infections in neutropenic patients treated for haematological malignancies are associated with a high mortality rate and, therefore, require early treatment. As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has bee...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200826010-00007

    authors: de Vries R,Daenen S,Tolley K,Glasmacher A,Prentice A,Howells S,Christopherson H,de Jong-van den Berg LT,Postma MJ

    更新日期:2008-01-01 00:00:00

  • Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

    abstract:BACKGROUND:Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer's disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200220090-00006

    authors: Garfield FB,Getsios D,Caro JJ,Wimo A,Winblad B

    更新日期:2002-01-01 00:00:00

  • Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

    abstract::Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199600093-00015

    authors: Jefferson T,Demicheli V

    更新日期:1996-01-01 00:00:00

  • The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.

    abstract:OBJECTIVES:(i) To project vaccine parameters, economic consequences and market size associated with HIV-1 vaccination of infants in sub-Saharan Africa through the Expanded Program on Immunisation (EPI); and (ii) to assess threshold values for price and effectiveness. STUDY DESIGN AND METHODS:Cost-effectiveness analysi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119090-00005

    authors: Bos JM,Postma MJ

    更新日期:2001-01-01 00:00:00

  • Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.

    abstract:OBJECTIVE:The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the in...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-016-0474-0

    authors: Fust K,Li X,Maschio M,Villa G,Parthan A,Barron R,Weinstein MC,Somers L,Hoefkens C,Lyman GH

    更新日期:2017-04-01 00:00:00

  • A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

    abstract:OBJECTIVE:The study aimed to conduct a systematic literature search to identify health state utilities for weight change in type 2 diabetes mellitus (T2DM) and to review those values for appropriateness for inclusion in a submission to the National Institute for Health and Clinical Excellence (NICE). METHODS:The searc...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11599420-000000000-00000

    authors: Doyle S,Lloyd A,Moore L,Ray J,Gray A

    更新日期:2012-12-01 00:00:00

  • Measuring the effect of cancer on health-related quality of life.

    abstract::Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199507040-00005

    authors: Osoba D

    更新日期:1995-04-01 00:00:00

  • Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.

    abstract:UNLABELLED:Cyclosporin microemulsion (Neoral) is a self-emulsifying preconcentrate of cyclosporin which is more rapidly and consistently absorbed than the original oil-based formulation of cyclosporin (standard formulation; Sandimmun, Sandimmune). This superior pharmacokinetic profile suggests that cyclosporin microemu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199814060-00009

    authors: Coukell AJ,Plosker GL

    更新日期:1998-12-01 00:00:00

  • Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy. An illustrative example focusing on the primary prevention of coronary heart disease in Canada.

    abstract:OBJECTIVE:To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. DESIGN AND SETTING:An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cos...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199916020-00008

    authors: Morris S,Godber E

    更新日期:1999-08-01 00:00:00

  • The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events.

    abstract::The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopid...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析,多中心研究

    doi:10.2165/00019053-200422004-00006

    authors: Weintraub W,Jönsson B,Bertrand M

    更新日期:2004-01-01 00:00:00

  • Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

    abstract::Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199712060-00008

    authors: Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

    更新日期:1997-12-01 00:00:00

  • Decision analysis in formulary decision making.

    abstract::Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199303060-00005

    authors: Schechter CB

    更新日期:1993-06-01 00:00:00

  • Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

    abstract::The progressive disability of Parkinson's disease results in substantial burdens for patients, their families and society in terms of increased health resource use, poorer quality of life, caregiver burden, disrupted family relationships, decreases in social and leisure activities, deteriorating emotional well-being, ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119070-00003

    authors: Rubenstein LM,DeLeo A,Chrischilles EA

    更新日期:2001-01-01 00:00:00

  • After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

    abstract::The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00882-6

    authors: Sculpher M,Palmer S

    更新日期:2020-03-01 00:00:00

  • The dilemma of new drugs. Are costs rising faster than effectiveness?

    abstract::This century has seen a phenomenal growth in the development, understanding and use of pharmaceuticals. Additionally, this period has seen the balance of the treatment needs of patients shift dramatically from infectious to cardiovascular and cancer diseases, and from infancy and middle-age to old age. The value of mo...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199813060-00001

    authors: Mason J,Freemantle N

    更新日期:1998-06-01 00:00:00

  • Economic aspects of pharmacotherapy for chronic constipation.

    abstract::Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199507010-00003

    authors: Passmore AP

    更新日期:1995-01-01 00:00:00

  • Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

    abstract:BACKGROUND:Recent randomised trials have demonstrated a statistically significant effect of trastuzumab on disease-free survival when used as adjuvant therapy for human epidermal growth factor receptor 2 protein (HER2)-positive resectable early stage breast cancer, with a treatment course lasting either 9 or 52 weeks. ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725050-00006

    authors: Millar JA,Millward MJ

    更新日期:2007-01-01 00:00:00

  • Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.

    abstract::Pneumocystis carinii pneumonia (PCP) is the most common severe opportunistic infection, and one of the most costly, among people with AIDS. Over 50% of patients experience toxic effects of the major anti-PCP medications- cotrimoxazole (trimethoprim-sulfamethoxazole) and pentamidine. Recently, the US Food and Drug Admi...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199609060-00007

    authors: Zarkin GA,Bala MV,Wood LL,Bennett CL,Simpson K,Dohn MN

    更新日期:1996-06-01 00:00:00

  • Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

    abstract:OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321070-00005

    authors: Maetzel A,Ruof J,Covington M,Wolf A

    更新日期:2003-01-01 00:00:00

  • On individual preferences and aggregation in economic evaluation in healthcare.

    abstract::For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119040-00001

    authors: Liljas B,Lindgren B

    更新日期:2001-01-01 00:00:00

  • Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.

    abstract:INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624080-00007

    authors: Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

    更新日期:2006-01-01 00:00:00

  • Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?

    abstract::Community-acquired pneumonia (CAP) is a common diagnosis and care of CAP is responsible for significant healthcare expenditures, the majority of which are for patients who require hospitalisation. Studies have shown that significant variation exists among institutions with respect to antibacterial costs and length of ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200422070-00001

    authors: Brown PD

    更新日期:2004-01-01 00:00:00

  • Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.

    abstract::Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

    journal_title:PharmacoEconomics

    pub_type: 已发布勘误

    doi:10.1007/s40273-018-0754-y

    authors: Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

    更新日期:2019-02-01 00:00:00

  • Integer/linear mathematical programming models: a tool for allocating healthcare resources.

    abstract::In today's environment, the demand for efficient healthcare resource allocation is increasing. As new technologies become available, allocation decisions become more complex and tools to assist decision makers in determining efficient allocations of healthcare resources are encouraged. Mathematical programs have multi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321120-00001

    authors: Earnshaw SR,Dennett SL

    更新日期:2003-01-01 00:00:00

  • The state of health economic research in South Africa: a systematic review.

    abstract:BACKGROUND:Economic factors are a limiting factor toward the implementation of many health programmes and interventions. Economic evaluation has a great potential to contribute toward cost-effective healthcare delivery in South Africa. Little is known about the characteristics and quality of health economic (including ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589450-000000000-00000

    authors: Gavaza P,Rascati KL,Oladapo AO,Khoza S

    更新日期:2012-10-01 00:00:00

  • Clinical and economic factors important to anaesthetic choice for day-case surgery.

    abstract::Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery, amnesia for the surgica...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200017030-00003

    authors: Eger EI,White PF,Bogetz MS

    更新日期:2000-03-01 00:00:00

  • Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.

    abstract::The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199610010-00006

    authors: Payne K,Kozma CM,Lawrence BJ

    更新日期:1996-07-01 00:00:00

  • Replicating Health Economic Models: Firm Foundations or a House of Cards?

    abstract::Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0553-x

    authors: Bermejo I,Tappenden P,Youn JH

    更新日期:2017-11-01 00:00:00

  • Discrete Choice Experiments in Health Economics: Past, Present and Future.

    abstract:OBJECTIVES:Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0734-2

    authors: Soekhai V,de Bekker-Grob EW,Ellis AR,Vass CM

    更新日期:2019-02-01 00:00:00